Goldman Sachs analyst Salveen Richter raised the firm’s price target on Apellis (APLS) to $26 from $24 and keeps a Neutral rating on the shares. The company’s Syfovre sales benefited from 6% q/q injection growth, despite a $13M negative impact on increased sample usage due to co-pay assistance funding shortages, and the stock traded up 17% as Syfovre met Street expectations, the analyst tells investors in a research note. The positive price action also reflects recognition of growth levers for Apellis through Empaveli in C3G/IC-MPGN, where the firm sees upside to the company’s addressable market estimates, Goldman Sachs added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- 3 Best Stocks to Buy Now, 7/31/2025, According to Top Analysts
- Apellis reports Q2 EPS (33c), consensus (47c)
- Apellis price target raised to $22 from $20 at Scotiabank
- Buy Rating for Apellis Pharmaceuticals Driven by FDA Approval and Promising Financial Projections for Empaveli
- Positive Outlook for Apellis Pharmaceuticals Following Empaveli Approval